Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
As CEO of one of the first companies to make protein delivery into a profitable business, Abe Abuchowski knows what it takes to bring a new technology to market. Although his technology—PEGylation—is now considered an industry gold standard, its three-decade development history illustrates the often rocky path to commercial success for platforms.
Collaborative development financing could offer a more objective validation than a standard licensing deals because selection is based on the intrinsic value of the compounds, rather than strategic considerations that often sway a big pharma.
Biotech companies are now in a race to go beyond the limitations of existing targeted therapies either by finding complementary treatments or by combining already approved therapies to synergize their effect
In May, Merck, one of the oldest and stodgiest pharmaceutical companies, entered the biotech arena by announcing its plans to purchase two protein manufacturing firms: GlycoFi for $400 million and Abmaxis for $80 million.
A flurry of investment activity during the first months of 2006 is evidence that some investors are waking up to the untapped market potential of a range of widely occurring gastrointestinal (GI) conditions that are as yet not well served.
The US Securities and Exchange Commission (SEC) has heard the plea of small biotechs that are overwhelmed by Sarbanes-Oxley (SOX) financial accounting compliance costs.
Exelixis is reaping the benefits of a licensing and development deal with GlaxoSmithKline that gives the pharma partner an option on 3 of 12 specified products in development.
Passion and perseverance have seen Elliot Entis down the long road of bringing transgenic salmon to market. His experiences 'swimming upstream' in animal biotech shows that endurance is key in bringing pioneering technologies to market.
Essentially the acquisition of a public company shell by a privately-held company in order access public capital, the reverse merger is, nowadays, a validated way of raising funds.
Pension managers may be warming up to the idea that much needed high rewards for their funds could come from investing in the high risk private equity biotech sector.
As AtheroGenics prepares to wrap up phase 3 trial sites for its lead atherosclerosis compound, small molecule AGI-1067, the future could suddenly become very bright for this tiny research company based in Alpharetta, Georgia.
When US President George Bush visited India in March this year a land mark deal on agriculture and biotech that went virtually unnoticed is now at the center of a controversy.
Divergent views among European Union member states on human embryonic stem cell research could hamper the creation of a much awaited new regulatory framework to address the sale and marketing of cell therapies and tissue-engineered products.
One of the youngest CEOs in the industry is going against conventional drug development by combining approved drugs in the hope to find a multi-targeted drug cocktail to deliver on the promises of the postgenomic era.
